CombinatoRx, Incorporated (NASDAQ:CRXX)

CombinatoRx, Incorporated (NASDAQ: CRXX) is a biopharmaceutical company focused on developing synergistic combinations of approved drugs using its proprietary combination high throughput screening (cHTS) technology. The company’s lead product candidate is CRx-102, a novel dissociated immuno-inflammatory glucocorticoid product candidate under Phase IIb clinical development for osteoarthritis and rheumatoid arthritis. Other products include CRx-139, a dissociated glucocorticoid product candidate; CRx-191, a topical synergistic combination drug candidate; and CRx-197, a novel topical anti-inflammatory product candidate. For further information, visit the Company’s web site at www.combinatorx.com.